Silibinin-induced apoptosis in MCF7 and T47D human breast carcinoma cells involves caspase-8 activation and mitochondrial pathway

Cancer Investigation

Volumn 29, Issue 1, 2011, Pages 12-20

  Tiwari, Prabha ^a   Kumar, Amit ^a   Balakrishnan, S ^a   Kushwaha, H S ^a   Mishra, K P ^a,b  

^a BHABHA ATOMIC RESEARCH CENTRE   (India)

^b Nehru Gram Bharati University   (India)

Author keywords

Apoptosis; Caspase 8 3; DNA fragmentation; Mitochondrial changes; Silibinin

Indexed keywords

CASPASE 8; PROTEIN P53; SILIBININ;

APOPTOSIS; ARTICLE; BREAST CARCINOMA; BREAST TUMOR; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CELL PROLIFERATION; CELL TYPE; CLONOGENESIS; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MITOCHONDRION; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BREAST NEOPLASMS; CASPASE 8; CELL LINE, TUMOR; CELL PROLIFERATION; DNA FRAGMENTATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; FEMALE; HUMANS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MITOCHONDRIA; PROTO-ONCOGENE PROTEINS C-BCL-2; SILYMARIN; TIME FACTORS;

EID: 78650447035     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357907.2010.535053     Document Type: Article

References (39)

1. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2000: CancerIncidence,Morality and PrevalenceWorldwide,Version 1.0. IARCCancer Base No. 5. Lyon, France: IARC Press, 2001
2. Warren R. Screening women at high risk of breast cancer on thebasis of evidence. Euro J Radiol 2001;39:50-59.
3. Sun S, Hail N Jr., Lotan R. Apoptosis as a novel target for cancerchemoprevention. J Natl Cancer Inst 2004;96:662-672.
4. Bold RJ, Termuhlen PM, McConkey DJ. Apoptosis, cancer andcancer therapy. Surgical Oncol 1997;6:133-142.
5. Moreira LM, Naomoto Y, Hamada M, Kamikawa Y, Orita K.Assessment of apoptosis in esophageal carcinoma preoperativelytreated by chemotherapy agents. Anticancer Res 1995;15: 639-644.
6. Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell2004;116:205-219.
7. Borst P, Rottenberg S, Jonkers J. How do real tumors become resistantto cisplatin? Cell Cycle 2008;15:1353-1359.
8. McWhinney SR, Goldberg RM, McLeod HL. Platinum neurotoxicitypharmacogenetics. Mol CancerTher 2009;8:10-16.
9. Tsuda H, Ohshima Y, Nomoto H, Fujita K, Matsuda E, Iigo M,Takasuka N, Moore MA. Cancer prevention by natural compounds.Drug Meta Pharmacokinet 2004;19:245-263.
10. Galati G, O'Brien PJ. Potential toxicity of flavonoids and other dietaryphenolics: significance for their chemopreventive and anticancerproperties. Free Radical Biol Med 2004;37:287-303.
11. Brownson DM, Azios NG, Fuqua BK, Dharmawardhane SF.Flavonoid effects relevant to cancer. J Nutr 2002;132:3482-3489.
12. Wellington K, Jarvis B. Silymarin: a review of its clinical propertiesin the management of hepatic disorders. Bio Drugs 2001;15:465-489.
13. Kaur M, Agarwal R. Silymarin and epithelial cancer chemoprevention:How close we are to bedside? Toxicol Appl Pharmacol2007;224:350-359.
14. Flaig TW, Gustafson DL, Su L, Zirrolli JA, Crighton F, HarrisonGS, Pierson AS, Agarwal R, Glode LM. A phase I and pharmacokineticstudy of silybin-phytosome in prostate cancer patients.Investig New Drugs 2007;25:139-146.
15. Zi X, Feyes DK, Agarwal R. Anticarcinogenic effect of a flavonoidsantioxidant, silymarin, in human breast cancer cells MDA-MB468: Induction of G1 arrest through an increase in Cip1/p21 concomitantwith a decrease in kinase activity of cyclin-dependent kinasesand associated cyclins. Clin Cancer Res 1998;4:1055-1064.
16. Vojtesek B, Lane DP. Regulation of p53 protein expression in humanbreast cancer cell lines. J Cell Sci 1993;105:607-612. (Pubitemid 23243193)
17. Jänicke RU, Sprengart ML,Wati MR, Porter AG. Caspase-3 is requiredfor DNA fragmentation and morphological changes associatedwith apoptosis. J Biol Chem 1998;273:9357-9360.
18. Zapata JM, Krajewski M, Krejewski S, Huang R, Takayama S,Wang H, Adamson E, Reed JC. Expression of multiple apoptosisregulatory genes in human breast cancer cell lines and primarytumors. Breast Cancer Res Treat 1998;47:129-140.
19. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependentapoptosis modulates the cytotoxicity of anticanced agents. Cell1993;74:957-967.
20. Blanc C, Deveraux QL, Krajewski S, Janicke RU, Porter AG, ReedJC, Jaggi R, Marti A. Caspase 3 is essential for procaspase 9 procressingand cisplatin induced apoptosis of MCF-7 breast cancercells. Cancer Res 2000;60:4386-4390.
21. Mooney LM, Al-Sakkaf KA, Brown BL, Dobson PRM. Apoptoticmechanisms in T47D and MCF-7 human breast cancer cells. Br JCancer 2002;87:909-917.
22. Kumar B, Joshi J, Kumar A, Pandey BN, Hazra B, MishraKP. Radiosensitization by diospyrin diethylether in MCF-7breast carcinoma cell line. Mol Cell Biochem 2007;304:287-296.
23. Kumar B, Kumar A, Pandey BN, Hazra B, Mishra KP. Enhancementof radiation-induced cytotoxicity in fibrosarcoma tumor inmurine models, as well as in a human cell line, by diospyrin diethylether.Int J Radiat Biol 2008;84:429-440.
24. KroemerG, ReedJC.Mitochondrial control of cell death. NatMed2000;6:513-519.
25. Kumar B, Kumar A, Pandey BN, Hazra B,Mishra KP. Role of mitochondrialoxidative stress in the apoptosis induced by diospyrindiethylether in human breast carcinoma (MCF-7) cells. Mol CellBiochem 2009;320:185-195.
26. Wharton DC, Tzagoloff A. Cytochrome oxidase from beef heartmitochondria. Methods Enzymol 1967;10:245-250.
27. Wang HJ, Tashiro S, Onodera S, Ikejima T. Inhibition of insulinlikegrowth factor 1 receptor signaling enhanced silibinin-inducedactivation of death receptor and mitochondrial apoptotic pathwaysin human breast cancer MCF-7 cells. J Pharmacol Sci 2008;107:260-269.
28. VenkatachalamS, Shi YP, Jones SN, Vogel H, Bradley A, Pinkel D,Donehower LA. Retention of wild-type p53 in tumors from p53heterozygous mice: reduction of p53 dosage can promote cancerformation. EMBO J 1998;17:4657-4667.
29. Kaina B. DNA damage-triggered apoptosis: critical role of DNArepair, double-strand breaks, cell proliferation and signaling.Biochem Pharmacol 2003;66:1547-1554.
30. Alkhalaf M, El-Mowafy AM. Overexpression of wild-type p53gene renders MCF-7 breast cancer cells more sensitive tothe antiproliferative effect of progesterone. J Endocrinology2003;179:55-62.
31. Kumar S. Mechanisms mediating caspase activation in cell death.Cell Death Diff 1999;6:1060-1066.
32. Reed JC. Regulation of apoptosis by bcl-2 family proteinsand its role in cancer and chemoresistance. Curr Opin Oncol1995;7:541-546.
33. Fulda S. Caspase-8 in cancer biology and therapy. Can Lett2009;281:128-133.
34. Mashima T, Tsuruo T. Defects of the apoptotic pathway as therapeutictarget against cancer. Drug Resis Updates 2005;8:339-343.
35. Liu X, Zou H,Widlak P, Garrard W, Wang X. Activation of theapoptotic endonuclease DFF40 (Caspase activated Dnase or nuclease).Oligomerisation and direct interaction with histone H1. JBiol Chem 1999;274:13836-13840.
36. Tang D, Kidd VJ. Cleavage of DFF-45/ ICAD by multiple caspasesis essential for its function during apoptosis. J Biol Chem1998;273:28549-28552.
37. Agarwal C, Singh RP, Dhanalakshmi S, Tyagi AK, TecklenburgM, Sclafani RA, Agarwal R. Silibinin upregulates the expressionof cyclin-dependent kinase inhibitors and causes cell cycle arrestand apoptosis in human colon carcinoma HT-29 cells. Oncogene2003;22:8271-8282.
38. Singh RP, Deep G, Chittezhath M, Kaur M, Dwyer-Nield LD,Malkinson AM, Agarwal R. Effect of silibinin on the growrh andprogression of primary lung tumors in mice. J Natl Cancer nst 2006;98:846-855.
39. Singh RP, Dhanalakshmi S, Tyagi AK, Chan DC, Agarwal C,Agarwal R. Dietary feeding of silibinin inhibits advance humanprostate carcinoma growth in athymic nude mice and increasesplasma insulin-like growth factor-binding protein-3 levels. CancerRes 2002;62:3063-3069.